Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg

C Ernst, D Bejko, L Gaasch, E Hannelas… - …, 2024‏ - pmc.ncbi.nlm.nih.gov
After Luxembourg introduced nirsevimab immunisation against respiratory syncytial virus
(RSV), estimated neonatal coverage was 84%(1,277 doses/1,524 births) in 2023. That year …

Burden of respiratory syncytial virus in adults in the United Kingdom: a systematic literature review and gap analysis

T Wilkinson, S Beaver, M Macartney… - Influenza and Other …, 2023‏ - Wiley Online Library
Despite the growing recognition of a potentially significant respiratory syncytial virus (RSV)
disease burden in adults, relevant evidence in the United Kingdom (UK) is limited. This …

Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis

B Cong, U Koç, T Bandeira, Q Bassat… - The Lancet Infectious …, 2024‏ - thelancet.com
Background The COVID-19 pandemic is reported to have affected the epidemiology of
respiratory syncytial virus (RSV), which could have important implications for RSV …

[HTML][HTML] Early and intense epidemic of respiratory syncytial virus (RSV) in Denmark, August to December 2022

C Munkstrup, FK Lomholt, HD Emborg… - …, 2023‏ - pmc.ncbi.nlm.nih.gov
In the autumn of 2022, Denmark witnessed the second out-of-season epidemic of respiratory
syncytial virus (RSV) following widespread societal preventive measures implemented …

Respiratory syncytial virus hospital-based burden of disease in children younger than 5 years, 2015-2022

RJ Suss, EAF Simões - JAMA Network Open, 2024‏ - jamanetwork.com
Importance Respiratory syncytial virus (RSV) resurgences have been noted following the
COVID-19 pandemic in many countries. Recent findings suggest that the 2021 and 2022 …

Resurgence of influenza and respiratory syncytial virus in Egypt following two years of decline during the COVID-19 pandemic: outpatient clinic survey of infants and …

A Kandeel, M Fahim, O Deghedy, WH Roshdy… - BMC Public Health, 2023‏ - Springer
Introduction Two years after unprecedented low rates of circulation of most common
respiratory viruses (SARS-CoV-2), the Egyptian ARI surveillance system detected an …

Reconstructing the impact of COVID-19 on the immunity gap and transmission of respiratory syncytial virus in Lombardy, Italy

HJ Ang, F Menegale, G Preziosi, E Pariani, M Migliari… - …, 2023‏ - thelancet.com
Background Respiratory syncytial virus (RSV) is a leading cause of hospitalisation and
mortality in young children globally. The social distancing measures implemented against …

[HTML][HTML] Genomic evolution of human respiratory syncytial virus during a decade (2013–2023): bridging the path to monoclonal antibody surveillance

M Piñana, A González-Sánchez, C Andrés, J Vila… - Journal of Infection, 2024‏ - Elsevier
Objectives This study investigated the prevalence, genetic diversity, and evolution of human
respiratory syncytial virus (HRSV) in Barcelona from 2013 to 2023. Methods Respiratory …

Global patterns of rebound to normal RSV dynamics following COVID-19 suppression

D Thindwa, K Li, D Cooper-Wootton, Z Zheng… - BMC Infectious …, 2024‏ - Springer
Background Annual epidemics of respiratory syncytial virus (RSV) had consistent timing and
intensity between seasons prior to the SARS-CoV-2 pandemic (COVID-19). However …

[HTML][HTML] Optimal respiratory syncytial virus intervention programmes using nirsevimab in England and Wales

D Hodgson, M Koltai, F Krauer, S Flasche, M Jit… - Vaccine, 2022‏ - Elsevier
Abstract Introduction Respiratory Syncytial Virus (RSV) is a major cause of acute lower
respiratory tract infections (ALRI) in infants. There are no licensed vaccines and only one …